pharma is the sole category represented across all 2 tracked stories. Wall Street Zen is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. At 5, the average consequence score sits below the same-window beat average of 5.5.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about B. Riley Financial
pharma is the sole category represented across all 2 tracked stories. Wall Street Zen is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. At 5, the average consequence score sits below the same-window beat average of 5.5. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 2 Biotech stories that mention B. Riley Financial, published between August 4, 2026 and August 8, 2026.
Stories tracked
2
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 32 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering B. Riley Financial. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.